dc.creator | Cummins, Joseph M. | |
dc.date.accessioned | 2019-06-17T16:55:11Z | |
dc.date.available | 2019-06-17T16:55:11Z | |
dc.date.issued | 1998-12-08 | |
dc.identifier.uri | https://hdl.handle.net/1969.1/176601 | |
dc.description.abstract | Autoimmune disorders are treated by the administration of human interferon, particularly IFN-α or IFN-β, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The interferon is administered in a solid dosage form, e.g., a saliva-dissolvable lozenge. | en |
dc.language | eng | |
dc.publisher | United States. Patent and Trademark Office | |
dc.rights | Public Domain (No copyright - United States) | en |
dc.rights.uri | http://rightsstatements.org/vocab/NoC-US/1.0/ | |
dc.title | Treatment of autoimmune disorders with oral interferon | en |
dc.type | Utility patent | en |
dc.format.digitalOrigin | reformatted digital | en |
dc.description.country | US | |
dc.contributor.assignee | The Texas A&M University System | |
dc.identifier.patentapplicationnumber | 08/476621 | |
dc.subject.uspcprimary | 424/85.7 | |
dc.subject.uspcother | 424/85.4 | |
dc.subject.uspcother | 424/85.6 | |
dc.subject.uspcother | 424/464 | |
dc.date.filed | 1995-06-07 | |
dc.publisher.digital | Texas A&M University. Libraries | |
dc.subject.cpcprimary | A61K 38/212 | |
dc.subject.cpcprimary | A61K 38/21 | |
dc.subject.cpcprimary | Y10S 435/811 | |